H. Trapl

Abstract GS3-01: A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy – results from 3,484 postmenopausal women in the ABCSG-16 trial

R. Greil, M. Gnant, P. Dubsky, 2018 .

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

R. Greil, T. Nielsen, S. Ferree, 2014, Clinical Cancer Research.

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer.

R. Greil, M. Gnant, R. Jakesz, 2021, The New England journal of medicine.

The PAM50 Risk-of-Recurrence Score Predicts Risk for Late Distant Recurrence after Endocrine Therapy in Postmenopausal Women with Endocrine-Responsive Early Breast Cancer

R. Greil, T. Nielsen, S. Ferree, 2014, Clinical Cancer Research.